Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Pulmozyme for Recanalization After Thrombectomy in Ischemic Stroke
2024-515831-31-00Phase 2Completed
- Sponsor
- Adolphe de Rothschild Foundation Hospital
- Start
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dornase alfa in ischemic stroke, sponsored by Adolphe de Rothschild Foundation Hospital. Primary endpoint: Complete arterial recanalization on post-thrombectomy angiography. Started Aug 2022; status: completed.
02
Drugs
dornase alfa
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-515831-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515831-31-00.